Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on Jun 19, 2022 2:33pm
228 Views
Post# 34767673

RE:RE:RE:Two valuation comps Akero and Seagen

RE:RE:RE:Two valuation comps Akero and SeagenA Gilead type offer from Pfizer would be my best-case scenario as it would take all the pressure off me to develop and execute an exit plan after all these SP roller coaster ride years…. Looking forward to the day my biggest pressure is figuring out how to do the best for my fellow man with that level of wealth…Pay it forward would be my guiding mantra…GO THERA!

SPCEO1 wrote: Since IMMU & SGEN were mentioned, I believe SGEN tried to buy IMMU fairly early in IMMU's development and IMMU shareholders shot it down. Hopefully, THTX gets a GILD-like offer and we shareholders never have to beat off a low ball one that comes too early.
 
<< Previous
Bullboard Posts
Next >>